AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DIMERIX LTD

0.435

-0.005-1.14%

Volume:450.95K

Turnover:197.22K

Market Cap:242.89M

PE:-9.84

High:0.445

Open:0.440

Low:0.430

Close:0.440

Loading ...

Overview Company News Filings

Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal

MT Newswires Live

BRIEF-Dimerix Receives Initial Upfront Payment From FUSO

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

The Market Herald

Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso

THOMSON REUTERS

BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln

Dimerix Ltd - Loss for Half-Year Attributable a$12.9 Mln

THOMSON REUTERS

Lowering Dimerix's Phase 3 Trial Hurdles to Boost Kidney Failure Treatment Drug Appeal, Euroz Hartleys Says.

MT Newswires Live

Emirates Takes Flight as First Autism-Certified Airline

ASX Market Close: Financials lead index higher | January 16, 2025

The Market Herald

Dimerix Recruits First Paediatric Patient for Kidney Disease Drug Trial

MT Newswires Live

Sparc fires up following three-way hydrogen tie-in

The Sydney Morning Herald

Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says

MT Newswires Live

ASX Market Update: Index rises as Trudeau resigns | January 7, 2025

The Market Herald

Dimerix Inks Exclusive License Deal With Fuso Pharmaceutical for Kidney Disease Drug Candidate; Shares Soar 23%

MT Newswires Live

BRIEF-Dimerix And FUSO Enter Into Exclusive Development And License Agreement To Commercialise DMX-200 In Japan

BUZZ-Australia's Dimerix jumps most in 1 year on drug development agreement for Japan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.435,"timestamp":1741151520000,"preClose":0.44,"halted":0,"volume":450954,"delay":0,"changeRate":-0.011364,"change":-0.005,"floatShares":437568654,"shares":558361086,"eps":-0.044195,"lyrEps":-0.0377,"pbRate":33.88,"amount":197223,"amplitude":0.034091,"volumeRatio":0.32863883296181856,"dividePrice":0,"prevYearClose":0.34,"fiveDayClose":0.48,"twentyDayClose":0.47},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":437568654,"roa":"-79.26%","roe":"-524.68%","lyrEps":-0.0377,"volumeRatio":0.32863883296181856,"shares":558361086,"dividePrice":0,"high":0.445,"amplitude":0.034091,"preClose":0.44,"low":0.43,"week52Low":0.26,"pbRate":"33.88","psRate":"329.17","week52High":0.665,"institutionHeld":0,"latestPrice":0.435,"eps":-0.044195,"divideRate":0,"volume":450954,"delay":0,"ttmEps":-0.044195,"open":0.44,"prevYearClose":0.34,"prevWeekClose":0.435,"prevMonthClose":0.435,"prevQuarterClose":0.34,"fiveDayClose":0.48,"twentyDayClose":0.47,"sixtyDayClose":0.355},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516136766","title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516136766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:32","pubTimestamp":1741059169,"startTime":"0","endTime":"0","summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XAO.AU","BK7501","DXB.AU","DMX","BK7508","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2516269987","title":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269987?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:23","pubTimestamp":1741051414,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSOMarch 4  - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF 300 MILLION FROM FUSO PHARMACEUTICAL INDUSTRIESDIMERIX RECEIVES INITIAL UPFRONT PAYMENT FROM FUSOANTICIPATES A FURTHER 400 MILLION FROM FUSOFurther company coverage: DXB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","DXB.AU","FSGS","BK7501","BK7067","DMX"],"gpt_icon":0},{"id":"2516666705","title":"Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666705?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:33","pubTimestamp":1741037617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0YV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"2514803966","title":"BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803966?lang=en_us&edition=fundamental","pubTime":"2025-02-25 12:36","pubTimestamp":1740458171,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 MlnFeb 25 (Reuters) - Dimerix Ltd DXB.AX:LOSS FOR HALF-YEAR ATTRIBUTABLE A$12.9 MILLIONFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","DXB.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2514704820","title":"Dimerix Ltd -  Loss for Half-Year Attributable a$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704820?lang=en_us&edition=fundamental","pubTime":"2025-02-25 06:08","pubTimestamp":1740434926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","DXB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2510721814","title":"Lowering Dimerix's Phase 3 Trial Hurdles to Boost Kidney Failure Treatment Drug Appeal, Euroz Hartleys Says.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510721814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510721814?lang=en_us&edition=fundamental","pubTime":"2025-02-11 07:40","pubTimestamp":1739230827,"startTime":"0","endTime":"0","summary":"Lowering the approval hurdles in Dimerix's (ASX:DXB) Phase 3 trial is expected to boost the success, value, and appeal of the company's kidney failure therapy, DMX-200, to potential US partners, accor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2505974112","title":"Emirates Takes Flight as First Autism-Certified Airline","url":"https://stock-news.laohu8.com/highlight/detail?id=2505974112","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505974112?lang=en_us&edition=fundamental","pubTime":"2025-01-21 13:52","pubTimestamp":1737438735,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta -Dubai-based airline Emirates announced that they have become the world's first Autism Certified Airline  carrier. This achievement is the result of a collaborative effort with the International Board of Credentialing and Continuing Education Standards  to establish more inclusive travel standards and services for passengers with autism and sensory sensitivities.As reported on the official Emirates website, this initiative is designed to transform air travel into a more accessible and friendly experience for individuals who require additional support during flights.","market":"other","thumbnail":"https://statik.tempo.co/data/2019/01/13/id_811238/811238_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2019/01/13/id_811238/811238_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1966397/emirates-takes-flight-as-first-autism-certified-airline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4129","BK7508","LU0274383776.USD","BK7501","DXB","BK7067","IE00B19Z6F94.USD","IE0034390439.USD","DXB.AU","ACA"],"gpt_icon":0},{"id":"2503322209","title":"ASX Market Close: Financials lead index higher | January 16, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503322209","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503322209?lang=en_us&edition=fundamental","pubTime":"2025-01-16 14:04","pubTimestamp":1737007440,"startTime":"0","endTime":"0","summary":"The ASX200 closed up 1.38% at 8,327 points.Unemployment ticked up to 4%, in line with consensus expectations. The strong jobs data has increased the threshold on what the RBA will need to see in the December quarter inflation numbers for any chance of a February rate cut.Moody’s Harry Murphy Hughes says underlying inflation at or under 3.2% year on year  would probably do the trick. And anything above that would likely see the board wait until May. Moody’s expect underlying inflation to come in at 3.3%.The Financials sector was the best performer, up 2.5%, followed by Real Estate, up 2.25%, and IT, up 1.8%.Helios Energyclosed up 14.3% after an independent contingent resource report confirmed hydrocarbon resources at the Presidio Project in West Texas.BHP closed up 0.5% after finalising a major acquisition with Lundin Mining, securing the full ownership of Filo Corp. and establishing a joint venture for the Filo del Sol and Josemaria copper projects in Argentina and Chile.Vulcan Energy ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-financials-lead-index-higher-january-16-2025-2025-01-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4516","BK7508","IE00BKVL7J92.USD","LU1989772840.SGD","BK7130","BK7145","BK7511","LU0098860793.USD","LU0320765646.SGD","LU2271345857.HKD","BHP.AU","LU0158827948.USD","LU0267386448.USD","LU0971096721.USD","LU1989772923.USD","LU2089284900.SGD","360.AU","BK7142","IE00BZ1G4Q59.USD","LU1162221912.USD","LU2023251221.USD","LU1732799900.SGD","ORG.AU","VUL.AU","LU0006306889.USD","LU1720051108.HKD","LU1074936037.SGD","LU0314104364.USD","LU1732800096.USD","LHM.AU","HE8.AU","LU2357305700.SGD","LU2089283258.USD","BK7067","LU0225283273.USD","BK4127","LU2028103732.USD","DXB.AU","LU0106831901.USD","LU0795875086.SGD","BK4581","LU1548497426.USD","BK7006","LU1668664300.SGD","LU2111349929.HKD","BK7504","LU0795875169.SGD","LU2347655156.SGD","BK4585","BK7016"],"gpt_icon":0},{"id":"2503989334","title":"Dimerix Recruits First Paediatric Patient for Kidney Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503989334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503989334?lang=en_us&edition=fundamental","pubTime":"2025-01-16 10:04","pubTimestamp":1736993040,"startTime":"0","endTime":"0","summary":"Dimerix  recruited the first paediatric patient for the phase-three clinical trial for DMX-200, the company's drug candidate for kidney disease, according to a Thursday filing with the Australian bourse.The biopharmaceutical company is assessing the efficacy and safety of DMX-200 in patients with focal and segmental glomerulosclerosis , a rare disease that attacks the kidney's filtering units, per the filing.A total of 19 specialist paediatric clinical sites across Argentina, Mexico, the UK, and the US will recruit patients into the clinical trial.The biopharmaceutical company expects the blinded interim analysis in August.Dimerix's shares were up 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","FSGS","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2502839668","title":"Sparc fires up following three-way hydrogen tie-in","url":"https://stock-news.laohu8.com/highlight/detail?id=2502839668","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502839668?lang=en_us&edition=fundamental","pubTime":"2025-01-10 14:09","pubTimestamp":1736489340,"startTime":"0","endTime":"0","summary":"This week the market again encountered a diverse mix of high-flying winners, with those finding favour on the market comprising a new-age hydrogen tech developer, an immune-related disorder biopharma firm, a mining company growing its scandium critical mineral resource and a drug developer joining forces with a Japanese pharmaceutical firm to fight kidney disease.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/sparc-fires-up-following-three-way-hydrogen-tie-in-20250110-p5l3fv.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["DXB.AU","AUZ.AU","BK7508","RGT.AU","BK7036","BK7096","BK7504","BK7501","SPN.AU","BK7067","BK7095"],"gpt_icon":0},{"id":"2502270057","title":"Dimerix Exclusive Japan Licensing Deal 'Positive Suprise,' Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2502270057","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502270057?lang=en_us&edition=fundamental","pubTime":"2025-01-09 13:41","pubTimestamp":1736401282,"startTime":"0","endTime":"0","summary":"Dimerix's  exclusive licensing agreement in Japan for its kidney disease drug candidate is a \"positive surprise,\" presenting additional value for the firm in the region, according to a Thursday note from Euroz Hartleys.Dimerix disclosed Tuesday that it entered into an exclusive development and license agreement worth a total of AU$107 million with Fuso Pharmaceutical Industries to develop and commercialize its drug candidate, DMX-200, to treat focal segmental glomerulosclerosis  in Japan.The Fuso licensing deal, Dimerix's third such deal, validates the ability of the firm's management to license across multiple territories, including in key markets like the US and Mainland China.Collectively, these licensing deals provide the company up to AU$458 million in upfront and potential milestone payments, as well as royalties on net sales.Importantly, Fuso, as a leading firm in the dialysis and renal/urology field, is well-positioned as an ideal partner for Dimerix in the region, the note sai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7067","FSGS","BK7508"],"gpt_icon":0},{"id":"2501454452","title":"ASX Market Update: Index rises as Trudeau resigns | January 7, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501454452","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501454452?lang=en_us&edition=fundamental","pubTime":"2025-01-07 10:42","pubTimestamp":1736217720,"startTime":"0","endTime":"0","summary":"The ASX200 has been up one fifth of a percent  at 8,273 points in afternoon trade.Canada’s Prime Minister Justin Trudeau has resigned and the country’s main stock index fell on Monday; the Loonie notched a near three-week high. Both moves come as investors weigh the uncertain timing of a potential shift in Canadian political power.Back home, IT has been the best performing sector, up 1.15%, followed by Telecommunication, up 0.85%, and Discretionary, up 0.75%.Utilities has been the biggest loser, down 1.35%, followed by Materials, down 0.25%, and Staples, down 0.2%.Dimerix has been up nearly 30% on news of a partnership with FUSO Pharmaceutical Industries, granting FUSO exclusive rights to develop, register, and commercialise Dimerix’s Phase 3 drug candidate inJapan.St George Mining  has been up 0.47% after locking in $20M of funding for the acquisition of advanced high-grade Araxá Niobium-REE Project in Brazil, the world’s leading niobium address.Nine Entertainment  has been up 4.8% an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-rises-as-trudeau-resigns-january-7-2025-2025-01-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7052","NEC.AU","BK7067","BK7508","BK7501","MMAT","DXB.AU","BK4141"],"gpt_icon":0},{"id":"2501137232","title":"Dimerix Inks Exclusive License Deal With Fuso Pharmaceutical for Kidney Disease Drug Candidate; Shares Soar 23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501137232","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501137232?lang=en_us&edition=fundamental","pubTime":"2025-01-07 09:24","pubTimestamp":1736213041,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) entered into an exclusive development and license agreement with Fuso Pharmaceutical Industries to develop and commercialize its drug candidate, DMX-200, for focal segmental glomerul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2501658290","title":"BRIEF-Dimerix And FUSO Enter Into Exclusive Development And License Agreement To Commercialise DMX-200 In Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501658290","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501658290?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:39","pubTimestamp":1736210351,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix And FUSO Enter Into Exclusive Development And License Agreement To Commercialise DMX-200 In JapanJan 7  - Dimerix Ltd DXB.AX:DIMERIX AND FUSO ENTER INTO EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT TO COMMERCIALISE DMX-200 IN JAPANFurther company coverage: DXB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O21KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","DXB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2501975472","title":"BUZZ-Australia's Dimerix jumps most in 1 year on drug development agreement for Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2501975472","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501975472?lang=en_us&edition=fundamental","pubTime":"2025-01-07 08:20","pubTimestamp":1736209234,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix jumps most in 1 year on drug development agreement for Japan** Shares of Dimerix DXB.AX rise as much as 31% to A$0.465, their biggest intraday pct gain since mid-October 2023** Biopharmaceutical firm enters exclusive agreement with Osaka-based FUSO Pharmaceutical Industries 4538.T to develop and commercialise kidney disease drug candidate DMX-200 in Japan** ASX-listed firm says it will receive 300 million Yen  within 40 days of signing the deal, with a potential additional 400 million Yen  expected upon the start of the first clinical trial site, anticipated in Q1 2025** Adds, the deal includes potential development and commercialisation milestones of up to 9.8 billion Yen , in addition to royalties ranging from 15% to 20% on net sales of the drug, if successfully commercialised** Stock hits its highest level since Oct. 21, 2024** Over 4.7 mln shares change hands, ~3.6x the 30-day avg** Dimerix gained 65.9% last year vs its Japanese peer's gains of 34.4%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nL4N3O21H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","DXB.AU","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":43}]}}